Health
Amgen Soars as CEO Touts Experimental Obesity Drug Progress
- Shares of Novo Nordisk, Lilly, Viking slump early Friday
- Amgen’s obesity therapy is still in mid-stage trials
This article is for subscribers only.
Amgen Inc.’s shares soared after its chief executive officer said he was “very encouraged” by early results from a study of the company’s experimental obesity drug, MariTide.
“We recognize the significant interest in obesity,” Amgen CEO Robert Bradway said Thursday on a call with investors. “We are confident in MariTide’s differentiated profile and believe it will address important unmet medical needs.”